Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 2Unspecified Childhood Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1Astrocytoma 1

Interventions

Carboplatin 43Paclitaxel 33Specimen Handling 15Taxes 14Cyclophosphamide 14Magnetic Resonance Spectroscopy 12Gemcitabine 12Biopsy 12Bevacizumab 12aldesleukin 11Immunoglobulin G 11Disulfides 11veliparib 9Topotecan 9Doxorubicin 9Cisplatin 9Docetaxel 8fludarabine 7olaparib 6liposomal doxorubicin 6Oxaliplatin 6Chemotherapy, Adjuvant 5talazoparib 4sargramostim 4pembrolizumab 4cediranib 4Nivolumab 4Fluorouracil 4Drug Therapy 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ovarian Neoplasms × irofulven × Clear all
NCT00019552 2013-06-20

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡